title: A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus.
abstract: BACKGROUND
  Insulin have been recommended to decrease glycosylated hemoglobin (HbA1c) level in type 2 diabetes mellitus (T2DM) patients whose blood glucose control are unsatisfactory by using oral hypoglycemic drugs.
  
  
  OBJECTIVE
  To systematically estimate the therapeutic effect and security of insulin glargine and insulin detemir for treatment of type 2 diabetes mellitus.
  
  
  METHODS
  We searched the Cochrane library, PubMed, EMBASE, etc databases. Quality evaluation of all randomized control tests (RCT) enrolled was conducted according to Cochrane manual, and meta-analysis was performed by using RevMan5.0 software.
  
  
  RESULTS
  Both insulin glargine and insulin detemir can effectively control T2DM patient's blood glucose.
  
  
  CONCLUSIONS
  Insulin detemir has evident superiority on reducing body weight than insulin glargine. As the doses are concerned, daily insulin dose of insulin detemir is higher than insulin glargine.
authors.affiliation: Department of Emergency, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. mmherofg@sina.com  
authors.forename: Y G
authors.initials: YG
authors.lastname: Zhuang
authors.forename: H
authors.initials: H
authors.lastname: Peng
authors.forename: F
authors.initials: F
authors.lastname: Huang
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; C517652:hemoglobin A1c protein, human